sgt-263(5F-CUMYL-P7AICA).

Description

Buy sgt-263(5F-CUMYL-P7AICA online

Also, it is not the first time that substances have been exclusively designed to evade generic definitions in national laws.buy sgt-263 online

It was reported that synthetic cannabinoid receptor agonist constituents of Spice were classified in the UK as Class B agents. This was in December 2009.

By the first quarter of 2017, 5F-CUMYL-P7AICA had been detected in 23% and 45% of test purchased herbal blends in Germany.

5F-CUMYL-P7AICA was detected at concentrations between 15-74 mg/g; average 39 mg/g.

As has been seen with other core structures, it is reasonable to anticipate the emergence of analogues.

There is potential for modification of the structure at the R1-R5 positions, or a combination.

Reports of 5F-CUMYL-P7AICA are already emerging.

We postulate three other potential analogues and propose nomenclature.

Other analogues are possible.

Following pharmacological evaluation, 5F-CUMYL-P7AICA demonstrated full agonistic activity and high potency at both CB1 and CB2 receptors.

In vitro and in vivo phase I metabolism studies have shown 5F-CUMYL-P7AICA to be extensively metabolized.

5F-CUMYL-P7AICA (also known as CUMYL-5F-P7AICA or SGT-263) is a pyrrolo[2,3-b]pyridine-3-carboxamide based synthetic cannabinoid that has been sold as a designer drug. It was first identified by the EMCDDA in February 2015.